The 2023 ESC Guidelines mentioned insulin as one of the major schemes for blood glucose management among CHF‐T2DM patients [5], yet many observational and clinical trial studies yielded contrasting conclusions regarding the consequence for insulin therapy receivers in CHF patients [6, 7, 8, 9, 10], due to differences in cardiac function across populations. This evidence concerns the gene INS and congestive heart failure.